Bonifay Doctor Settles Controlled Substances Act Violations For $130,000
Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( Lock A locked padlock ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

United States Drug Enforcement Administration

  • Get Updates
  • Scam Alert
  • Full Menu
  • English
  • Español

Main Menu

Explore DEA
  • Who We Are
    • About
    • Mission
    • History
    • Divisions
    • DEA Museum
    • Wall of Honor
    • Contact Us
  • What We Do
    • Forensic Sciences
    • Law Enforcement
    • Education and Prevention
    • Drug Information
    • News
    • Campaigns
  • Careers
    • Special Agent
    • Diversion Investigator
    • Intelligence Research Specialist
    • Forensic Sciences Careers
    • Professional & Administrative Careers
    • Student & Entry Level Careers
    • Employment Eligibility
    • How to Apply
  • Resources
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Data and Statistics
    • FOIA
    • Publications
    • Media Galleries
    • Victim Witness Assistance Program
  • Submit A Tip

Breadcrumb

  • Home
  • Bonifay Doctor Settles Controlled Substances Act Violations For $130,000

Bonifay Doctor Settles Controlled Substances Act Violations For $130,000

July 06, 2022
|
Share Article
|
Download Press Release
For Immediate Release
Contact:
Phone Number: (571) 362-3364 - Option 5

PENSACOLA, Fla. —Ahmad T. Ismail, 70, of Bonifay, Florida, settled potential violations of the Controlled Substances Act by agreeing to pay a fine of $130,000 and surrendering his Drug Enforcement Administration (DEA) registration.  The settlement was announced by Jason R. Coody, United States Attorney for the Northern District of Florida.

“A physician’s failure to adhere to the safeguards of the Controlled Substances Act can facilitate the diversion of addictive drugs, illegal distribution of those substances, and risk of overdose,” said U.S. Attorney Jason R. Coody. “With our law enforcement partners, we will continue to utilize both the civil and criminal provisions of the Controlled Substances Act to protect our communities and hold violators responsible.”

“As trusted members of the community, medical professionals are required to adhere to the federal laws regarding controlled substances as set forth in the Controlled Substances Act,” said DEA Miami Field Division Special Agent in Charge Deanne L. Reuter. “Our communities can rest assured that DEA will pursue civil actions against any DEA Registrant who violates these federal laws as well as the trust of the American public.”

Ismail entered into a civil settlement agreement with the United States Attorney’s Office for the Northern District of Florida. The terms of the settlement include a provision that Ismail will surrender his DEA registration and will not reapply for a period of at least three years. In addition, Ismail will pay a fine of $130,000. 

Beginning in December 2018, DEA investigators conducted a routine inspection of Ismail’s practice in Bonifay, Florida. During that inspection and subsequent investigation, they discovered numerous potential civil violations of the Controlled Substances Act, including:

  1. Failing to keep complete and accurate records, revealing significant discrepancies between the number of dosage units in inventory and the number of dosage units purchased using Dr. Ismail’s DEA registration number;
  2. Failing to complete a biennial inventory;
  3. Failing to maintain accurate and complete records of dispensation/administration of controlled substances;
  4. Failing to maintain complete and accurate dispensing records to include the name of the substance, quantity, date dispensed, address of person whom it was dispensed, the written or typewritten name or initials of the individual who dispensed the substance, the drug strength, and units in each container; and
  5. Failing to sign and date a controlled substance prescription on the date of issuance on at least two occasions.

This civil settlement agreement is not an admission of any liability by Dr. Ismail, nor a concession by the United States that its potential claims were not well-founded. 

The United States Attorney’s Office for the Northern District of Florida handled this matter, which was investigated by the Drug Enforcement Administration, Diversion Control Program, Tallahassee Resident Office. For more information about the United States Attorney’s Office, Northern District of Florida, visit http://www.justice.gov/usao/fln/index.html.

If you are aware of controlled substance violations in your community, please submit your anonymous tip through the DEA online Tip Line at Submit a Tip | DEA.gov.  Concerns about prescription drug abuse or diversion can be reported to the DEA through this link: RX Abuse Online Reporting (usdoj.gov).

Follow DEA Miami via Twitter at @DEAMIAMIDIV

Download Press Release
###
US Department of Justice - Drug Enforcement Administration

Drug Enforcement Administration

Deanne L. Reuter Special Agent in Charge - Miami
@deamiamidiv
  • Facebook
  • X
  • Email
  • Who We Are
    • About
    • Domestic Divisions
    • Foreign Offices
    • Contact Us
    • DEA Museum
  • What We Do
    • Forensic Sciences
    • Law Enforcement
    • Drug Prevention
    • Diversion Control Division
    • News
  • Careers
    • Special Agent
    • Diversion Investigator
    • Forensic Sciences
    • Intelligence Research Specialist
    • How to Apply
  • Resources
    • Drug Information
    • Employee Assistance Program
    • FOIA
    • Publications
    • Media Galleries
    • VWAP
  • Doing Business
    with the DEA
    • Overview
    • Current Vendors
    • Prospective Vendors
    • Security Clauses
    • Security Forms
    • Small Business Program
    • Vendor Engagement Request
  • Policies
    • Accessibility & Policy
    • Legal Policies & Disclaimers
    • No FEAR Act
    • Privacy Policy
    • U.S. Department of Justice EEO Policy
    • USA.gov
    • Whistleblower Protection
    • Your Rights as a Federal Employee

United States Drug Enforcement Administration

DEA.gov is an official site of the U.S. Department of Justice
Facebook X LinkedIn Instagram

DEA Contact Center

(202) 307-1000 info@dea.gov
Contact the Webmaster

United States Drug Enforcement Administration

Back
  • Who We Are
  • What We Do
  • Careers
  • Resources
Back
  • About
  • Mission
  • History
  • Divisions
  • DEA Museum
  • Wall of Honor
  • Contact Us
Back
  • Domestic Divisions
  • Foreign Divisions
  • Operational Divisions
Back
  • Submit a Tip
  • Extortion Scam
  • Public Affairs
  • Social Media Directory
Back
  • Forensic Sciences
  • Law Enforcement
  • Education and Prevention
  • Drug Information
  • News
  • Campaigns
Back
  • GUARDS
  • Forensic Sciences Policy
  • Forensic Science Organizations
  • Forensic Science Contact
Back
  • DEA Office of Training
  • El Paso Intelligence Center (EPIC)
  • Intelligence
  • Operations
Back
  • Office of Training Programs
Back
  • Administrative Law Judges
  • DEA Asset Forfeiture
  • Domestic Cannabis Suppression / Eradication Program
  • HIDTA
  • OCDETF
Back
  • Family Summit
  • Red Ribbon
  • Kiki and the History of Red Ribbon Week
  • Red Ribbon Toolkit - Resources For Your Community
  • DEA’s Family Summit
  • Operation Engage
  • Community Outreach
  • Just Think Twice
  • Campus Drug Prevention
  • Get Smart About Drugs
  • Operation Prevention
Back
  • Drug Policy
  • Drug Scheduling
  • The Controlled Substances Act
Back
  • Alerts
  • Press Releases
  • Most Wanted Fugitives
  • Stories
  • Events
  • Speeches
  • Testimony
Back
  • All Fugitives
Back
  • One Pill Can Kill
  • DEA National Prescription Drug Take Back Day
Back
  • Senior Citizens
  • Partner Toolbox
  • Social Media Campaign
Back
  • Special Agent
  • Diversion Investigator
  • Intelligence Research Specialist
  • Forensic Sciences Careers
  • Professional & Administrative Careers
  • Student & Entry Level Careers
  • Employment Eligibility
  • How to Apply
Back
  • Special Agent FAQs
Back
  • Diversion Investigator Job Announcement
Back
  • Intelligence Research Specialist Job Announcements
  • Intelligence Research Specialists FAQs
  • Schedule A Hiring Authority: Intelligence Research Specialist
Back
  • How To Claim Veterans' Preference
  • Priority Consideration
  • Benefits
  • Veterans and People With Disabilities
  • Operation Warfighter
Back
  • Illegal Online Pharmacies
  • OD Justice
  • Fentanyl Supply Chain
  • Pill Press Resources
  • Recovery Resources
  • Together for Families
  • Data and Statistics
  • FOIA
  • Publications
  • Media Galleries
  • Victim Witness Assistance Program
Back
  • Domestic Arrests
  • Staffing and Budget
Back
  • About FOIA
  • Contact DEA FOIA
  • Make a Request
  • What Happens After Making a Request
  • Requester Categories
  • Fees Charged
  • Fee Waiver
  • FOIA FAQ
  • FOIA Logs and Reports
  • FOIA Library
  • Additional FOIA Links
  • FOIA Exemptions
  • What Are Exclusions?
  • Privacy Act
  • Privacy Act Exemptions
  • Privacy Impact Assessment and Management Information Systems
Back
  • Victim Witness Assistance Program Resources
  • Human Trafficking Prevention
  • Submit A Tip +
  • Get Updates
  • Scam Alert
    • English
    • Español